Board Member
Arcus Biosciences, Inc. (RCUS)Board Member
Neurocrine Biosciences Inc (NBIX)Equibles does not estimate personal net worth.
Get an email with a short summary when Gilead Sciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get GILD alertsJohanna Mercier is recorded as Board Member at Arcus Biosciences, Inc. (RCUS) and Board Member at Neurocrine Biosciences Inc (NBIX) since January 1, 2021. The newest filing on record that lists Johanna Mercier as Board Member at Arcus Biosciences, Inc. (RCUS) is dated April 21, 2026. The newest filing on record that lists Johanna Mercier as Board Member at Neurocrine Biosciences Inc (NBIX) is dated April 15, 2026. Neurocrine Biosciences Inc reported in an 8-K filed May 28, 2026 a re-election or new board role (Class III Director) for Johanna Mercier, on the board since at least 2021, effective May 27, 2026. Arcus Biosciences, Inc. reported in an 8-K filed January 30, 2024 that Johanna Mercier was appointed Class II director, effective January 29, 2024. Neurocrine Biosciences Inc reported in an 8-K filed May 19, 2023 a re-election or new board role (Class III Director) for Johanna Mercier, on the board since at least 2021, effective May 17, 2023. The proxy statement of Gilead Sciences, Inc. reports total compensation of $9,300,643 for Johanna Mercier in fiscal 2025, including a base salary of $1,182,269. Disclosed compensation is on record for 7 fiscal years. Johanna Mercier has spoken on 7 earnings calls and 4 other investor events across 1 company, most recently for Gilead Sciences, Inc. on October 29, 2026. Gilead Sciences, Inc. is classified in the Drug Manufacturers - General industry within the Healthcare sector. Arcus Biosciences, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Gilead Sciences, Inc. includes Daniel P. O’Day (CEO), Robin L. Washington (CFO), Diane E. Wilfong (Chief Accounting Officer) and 7 others.
“The three nominees for Class III Director were elected.”
“On January 29, 2024 (i) Dr. Jaen and Ms. Jarrett resigned from the Board and (ii) following such resignations, the Board appointed Johanna Mercier to the Board as a Class II director.”
“Starting on slide 7, total product sales, excluding Viclory, of $8.2 billion were up 16% year-over-year, driven by strong HIV performance, Tredelvi, and Livdelzi.”
“I really think the Yes2Go launch is an incredible success thus far, and it really has a lot to do with the preparation of the marketplace, but also the work that we've done for the last 10, 12 years in prevention and really understanding the market, the consumers for PrEP.”
“This was another exceptional quarter of commercial execution across our core therapeutic areas. Starting on slide 7, total product sales, excluding Veclari, of $7.6 billion increased 10% year-over-year, driven by strong growth in Bictarvi, Discovi, and Yes2Go in HIV, Tridelvi in oncology, and Livdelzi in liver disease.”
“So Gilead Sciences is still a young company. It's just coming on to about 40 years or so, and one that is specialized across three therapeutic areas, some more developed than others, but HIV, oncology, and inflammation.”
“Lenacapivir is one of the most important advancements we've seen in HIV prevention, so I understand why there's a significant interest in how access is being handled.”
2021-01-01–present
Last confirmed April 15, 2026
Source not stated
Start not stated–present
Last confirmed April 21, 2026
Drug Manufacturers - General · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
Board Member
2021-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Gilead Sciences, Inc. (GILD) | Chief Commercial and Corporate Affairs Officer | $1,182,269 | $9,300,643 |
| 2024 | Gilead Sciences, Inc. (GILD) | Chief Commercial Officer | $1,148,038 | $8,609,065 |
| 2023 | Gilead Sciences, Inc. (GILD) | Chief Commercial Officer | $1,114,035 | $8,586,754 |
| 2022 | Gilead Sciences, Inc. (GILD) | Chief Commercial Officer | $1,081,471 | $9,236,453 |
| 2021 | Gilead Sciences, Inc. (GILD) | Chief Commercial Officer | $1,050,428 | $6,552,597 |
| 2020 | Gilead Sciences, Inc. (GILD) | Chief Commercial Officer | $1,059,135 | $7,776,911 |
| 2019 | Gilead Sciences, Inc. (GILD) | Chief Commercial Officer | $461,538 | $8,049,386 |
